Trials / Unknown
UnknownNCT04425135
Camrelizumab Combined With Apatinib Mesylate and Standard Chemotherapy (Pemetrixed + Carboplatin) in Patients With Tyrosine Kinase Inhibitor Failure in ALK-positive Advanced NSCLC
Phase II Single-arm Clinical Study of Camrelizumab Combined With Apatinib Mesylate and Standard Chemotherapy (Pemetrixed +Carboplatin) in Patients With Tyrosine Kinase Inhibitor Failure in ALK-positive Advanced NSCLC
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 59 (estimated)
- Sponsor
- The First Affiliated Hospital of Xiamen University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is a phase II single-arm clinical study.The purpose of this study was to evaluate the efficacy and safety of carrelizumab combined with apatinib mesylate and standard chemotherapy (pemetrexed plus carboplatin) in patients with advanced non-squamous and non-small cell lung cancer who have failed tyrosine kinase inhibitor therapy and are ALK-positive.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Camrelizumab | 200mg,D1,ivgtt, Q3w. |
| DRUG | Apatinib | 250mg,Qd,Q3W. |
| DRUG | Pemetrixed | 500 mg/m2,D1,ivgtt, Q3w. |
| DRUG | Carboplatin | AUC=5\~6,D1,ivgtt, Q3w. |
Timeline
- Start date
- 2020-07-01
- Primary completion
- 2023-01-01
- Completion
- 2025-01-01
- First posted
- 2020-06-11
- Last updated
- 2020-06-11
Source: ClinicalTrials.gov record NCT04425135. Inclusion in this directory is not an endorsement.